Novel HCV Drug Can Double Response Rate (CME/CE)
					(MedPage Today) -- An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.					                    
					
                     

Comments are closed.
(MedPage Today) — An investigational protease inhibitor aimed at blocking hepatitis C replication can double the response rate compared with standard care, researchers said.

Comments are closed.
All rights reserved. © UK. Site Map | Contact us | About us | Contributors | Supporters | Terms & Conditions
 
 This site complies with the  HONcode standard for trustworthy health information: 
verify here.
 This site complies with the  HONcode standard for trustworthy health information: 
verify here. 
 
  


